Clinical Trial Update: Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma

View source ↗

Summary

A completed neoadjuvant trial comparing nivolumab plus SOX versus nivolumab plus FLOT in HER2-negative gastric and gastroesophageal junction adenocarcinoma, eva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• 5-FU (5-fluorouracil)
• Eloxatin (oxaliplatin)
• Leucovorin (folinic acid)
• OPDIVO (nivolumab)
• S-1 (tegafur/gimeracil/oteracil)
• Taxotere (docetaxel)

Snippet

Sponsor: Xijing Hospital | Conditions: Immune-related Adverse Event, Chemotherapeutic Toxicity | Status: COMPLETED